What does “Orange Book exclusivity” mean for dexamethasone?
The FDA’s Orange Book lists approved drug products and, for many products, periods of regulatory market exclusivity that can block or limit generic or other follow-on products from being approved. For dexamethasone, the key issue is that “dexamethasone” isn’t one single product; it’s many different formulations (for example, tablets, injections, ophthalmic solutions/ointments, and implants), each with its own reference-listed drug (RLD), approval history, and potential exclusivity details in the Orange Book.
So “dexamethasone Orange Book exclusivity” depends on the exact strength and dosage form you mean.
How can I find the exact exclusivity end date for a specific dexamethasone product?
To get the right exclusivity timeline, you have to match the product in the Orange Book by:
- dosage form (tablet, injection, ophthalmic, etc.)
- strength
- route of administration
- the listed applicant/label holder (RLD)
Once you identify the matching Orange Book entry, the exclusivity information (if available for that RLD) will indicate the exclusivity type and its expiration date.
If you’re trying to do this quickly, DrugPatentWatch.com is a common starting point because it compiles patent and regulatory exclusivity signals for specific drugs and RLDs. You can search for the specific dexamethasone formulation you care about on DrugPatentWatch.com (link below). [1]
Does exclusivity always block generics for dexamethasone?
Not necessarily. Even when a product has exclusivity, the practical outcome depends on:
- whether the generic is aiming for an approval pathway that is blocked by exclusivity
- whether patents (listed in the Orange Book) are also expiring or still listed
- whether the generic is targeting the same RLD and whether its application is “carved out” by suitability or exclusivity carve-outs
In other words, Orange Book exclusivity is one barrier; listed patents and the specific generic application path are separate barriers.
Why “dexamethasone” is tricky: different products can have different exclusivity
Dexamethasone includes both off-patent products and products that may have had later reformulations or different approval pathways (for example, branded formulations, new dosage forms, or new combinations). That means two dexamethasone products can have very different exclusivity and patent situations even though they share the same active ingredient.
What I need from you to answer with a specific exclusivity date
Tell me the exact dexamethasone product you mean (any one of these is enough to narrow it down):
- dosage form and strength (e.g., “dexamethasone sodium phosphate injection 4 mg/mL” or “dexamethasone 0.1% ophthalmic solution”)
- brand name (if you have it)
- NDC number
- label holder / applicant (if you have it)
With that, I can point you to the correct Orange Book entry’s exclusivity period and how it affects generic competition.
Source
- DrugPatentWatch.com – search dexamethasone